You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 19, 2025

Details for Patent: 10,765,749


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,765,749 protect, and when does it expire?

Patent 10,765,749 protects ZTLIDO and is included in one NDA.

This patent has fourteen patent family members in eight countries.

Summary for Patent: 10,765,749
Title:Non-aqueous patch
Abstract: Non-aqueous patches comprising lidocaine, which is not dissolved and is present in a crystalline state, have poor permeability to the skin. Therefore, non-aqueous patches have a high concentration of lidocaine. It is pointed out that lidocaine has an adverse effect on the heart. Prolonged use of a high concentration of lidocaine causes side effects, such as shock, rubor, and irritating sensation. External preparations comprising more than 5 mass % of lidocaine are designated as powerful drugs, and cannot be used as household (nonprescription) medicine. Provided is a non-aqueous patch that is effective to relieve muscle pain, the non-aqueous patch comprising lidocaine and/or its reactant, and a dissolving agent composed of an organic acid and a polyalcohol, which are contained in a base.
Inventor(s): Mori; Tatsuya (Saga, JP), Saida; Naoyuki (Saga, JP)
Assignee: ITOCHU CHEMICAL FRONTIER Corporation (Tokyo, JP) OISHI KOSEIDO CO., LTD. (Saga, JP)
Application Number:15/891,915
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,765,749
Patent Claim Types:
see list of patent claims
Compound;
Patent landscape, scope, and claims:

United States Patent 10,765,749: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 10,765,749, titled "Non-aqueous patch," is a significant innovation in the field of transdermal drug delivery, particularly for relieving muscle pain. This patent, granted to ITOCHU CHEMICAL FRONTIER Corporation, introduces a novel formulation and design for non-aqueous patches containing lidocaine.

Technical Field

The patent falls under the technical field of pharmaceutical formulations, specifically transdermal drug delivery systems. It addresses the challenges associated with traditional aqueous patches, such as poor skin permeability and limited efficacy[2].

Background of the Invention

Traditional non-aqueous patches containing lidocaine often suffer from poor permeability through the skin due to the crystalline state of lidocaine. This limitation hampers the effective delivery of the drug, reducing its therapeutic efficacy. The inventors aimed to overcome this issue by developing a new formulation that enhances skin permeability and improves drug delivery.

Summary of the Invention

The patented non-aqueous patch includes lidocaine and/or its reactant, along with a dissolving agent. This combination ensures that lidocaine is not in a crystalline state, thereby improving its permeability through the skin. The patch is designed to be effective in relieving muscle pain without the need for aqueous components[1][2].

Detailed Description of the Invention

Components of the Patch

  • Lidocaine: The primary active ingredient, which is a well-known local anesthetic and pain reliever.
  • Dissolving Agent: This component is crucial as it prevents lidocaine from being in a crystalline state, enhancing its skin permeability.
  • Other Materials: The patch may include additional materials such as resins, polyisobutene, elastomers, and natural products like rosin and abietic acid, which contribute to its structural integrity and drug delivery properties[1].

Formulation

The formulation of the patch involves a careful balance of the active ingredient and the dissolving agent. This balance is critical to ensure that the lidocaine is in a state that allows for optimal skin penetration. The patent describes various methods for preparing the patch, including the use of specific solvents and manufacturing processes[2].

Manufacturing Process

The manufacturing process involves several steps, including the preparation of the lidocaine and dissolving agent mixture, the application of this mixture onto a backing material, and the drying process to form the final patch. The patent provides detailed descriptions of these steps to ensure reproducibility and consistency in the product[1].

Claims of the Patent

The patent includes several claims that define the scope of the invention:

  • Claim 1: A non-aqueous patch comprising lidocaine and a dissolving agent, where the lidocaine is not in a crystalline state.
  • Claim 2: The patch of claim 1, further comprising a resin and/or an elastomer.
  • Claim 3: The patch of claim 1, where the dissolving agent is selected from a group of specific compounds.
  • Claim 4: A method for preparing the non-aqueous patch, including the steps of mixing lidocaine with a dissolving agent and applying the mixture to a backing material[2].

Patent Landscape

Related Patents

The patent is part of a series of related applications and patents, including U.S. Pat. No. 9,931,403, U.S. Pat. No. 9,925,264, and U.S. Pat. No. 9,283,174. These patents collectively contribute to the development of advanced transdermal drug delivery systems[2].

International Patent Filings

The invention has been filed in various international jurisdictions, reflecting its global significance. The use of the Patent Cooperation Treaty (PCT) and national stage filings ensures broad protection across different countries[2].

Prior Art

The patent distinguishes itself from prior art by addressing the specific issue of lidocaine's poor skin permeability in non-aqueous patches. The introduction of a dissolving agent to prevent the crystallization of lidocaine is a novel approach that sets this invention apart from existing solutions[1].

Economic and Market Impact

Market Demand

The demand for effective transdermal pain relief solutions is high, driven by the need for non-invasive and convenient treatments. This patent fills a critical gap in the market by providing a more effective alternative to traditional patches.

Competitive Advantage

The unique formulation and design of the non-aqueous patch give ITOCHU CHEMICAL FRONTIER Corporation a competitive advantage in the pharmaceutical market. This innovation can lead to increased market share and revenue.

Legal and Regulatory Aspects

Patent Protection

The patent provides legal protection for the invention, preventing others from making, using, or selling the non-aqueous patch without permission. This protection is crucial for maintaining the company's competitive edge.

Regulatory Compliance

The development and commercialization of the patch must comply with regulatory requirements, including those set by the FDA. The patent does not address regulatory aspects directly but implies that the invention is designed to meet such standards.

Future Developments and Applications

Potential Applications

The technology behind this patent can be extended to other transdermal drug delivery systems, potentially treating a range of conditions beyond muscle pain.

Research and Development

Further research can focus on optimizing the formulation and exploring new dissolving agents to enhance the efficacy of the patch. This could lead to new patents and innovations in the field.

Key Takeaways

  • The United States Patent 10,765,749 introduces a novel non-aqueous patch for muscle pain relief using lidocaine.
  • The patch's unique formulation includes a dissolving agent to prevent lidocaine crystallization, enhancing skin permeability.
  • The patent is part of a broader series of related patents and international filings.
  • It addresses a significant market need for effective transdermal pain relief solutions.
  • The invention has the potential for future developments and applications in various therapeutic areas.

FAQs

Q: What is the main innovation of the United States Patent 10,765,749?

A: The main innovation is the use of a dissolving agent to prevent lidocaine from being in a crystalline state, thereby improving its skin permeability.

Q: What are the key components of the non-aqueous patch?

A: The key components include lidocaine, a dissolving agent, and other materials such as resins and elastomers.

Q: How does the manufacturing process of the patch ensure its efficacy?

A: The manufacturing process involves careful preparation of the lidocaine and dissolving agent mixture, application onto a backing material, and a controlled drying process.

Q: What is the significance of the patent in the market?

A: The patent fills a critical gap in the market for effective transdermal pain relief solutions, giving ITOCHU CHEMICAL FRONTIER Corporation a competitive advantage.

Q: Are there potential future applications of this technology?

A: Yes, the technology can be extended to other transdermal drug delivery systems for treating various conditions beyond muscle pain.

Sources

  1. US10765749B2 - Non-aqueous patch - Google Patents
  2. US Patent for Non-aqueous patch Patent (Patent # 10,765,749) - Justia Patents
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO
  5. Ex Parte Kucinski et al | 10765749 | P.T.A.B. | Judgment | Law - CaseMine

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,765,749

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
Scilex Pharms ZTLIDO lidocaine PATCH;TOPICAL 207962-001 Feb 28, 2018 RX Yes Yes 10,765,749 ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 1 of 1 entries

International Family Members for US Patent 10,765,749

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Brazil 112013028802 ⤷  Subscribe
Brazil 122021017591 ⤷  Subscribe
Canada 2835595 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.